why choose us

First received: February 13, 2023

Clinical Trial: Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Cancer

Study Type: INTERVENTIONAL


Official Title: A Prospective Trial of Stereotactic Adaptive Radiation Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer: An Individualized Approach to Minimizing Gastrointestinal Toxicity (AR

Brief Summary: This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity.The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.

Read more